UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2014

MATINAS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

(Commission File Number)

1545 Route 206 South, Suite 302 Bedminster, New Jersey (Address of principal executive offices) 46-3011414 (IRS Employer ID Number)

> 07921 (Zip Code)

Registrant's telephone number, including area code: (908) 443-1860

Not Applicable (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Matinas BioPharma Holdings, Inc. (the "Company") intends to use a slide presentation in connection with certain investor meetings. The slide presentation is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

This Current Report on Form 8-K, including exhibit 99.1, contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forwardlooking statements include words such as "expects," "anticipates," "intends," "plans," "could", "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Matinas does not undertake any obligation to release publicly any revisions to such forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's lead product candidate MAT9001 is in a development stage and is not available for sale or use.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautions not to place undue reliance on any forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01.	Financial Statements and Exhibits	
Exhibit	Description	
99.1	Slide Presentation	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MATINAS BIOPHARMA HOLDINGS, INC.

Date: August 8, 2014

/s/ Roelof Rongen Roelof Rongen, President and Chief Executive Officer



Forward Looking Statement

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could", "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forwardlooking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Matinas does not undertake any obligation to release publicly any revisions to such forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's lead product candidate MAT9001 is in a development stage and is not available for sale or use.






MATINAS

Team out of Reliant Pharmaceuticals (Lovaza®) with strong development & commercialization track record

Unique and differentiating expertise in lipidomics and lipid chemistry

Historical lack of innovation/investment in lipid-based therapies

Initial focus on lower risk hypertriglyceridemia opportunity in a large and growing metabolic/CV disease arena





Lack of Good Prescription Options


Medical Center	PRESCRIPTIO	DL-LOWERING NS – 2012 & 20 scriptions TRx	
Address Date R Side Effects/ Lack of Benefit Total prescriptions -7% YOY MD		2.5M /yr lost 32.5 2013	
MATINAS	Source: IMS		6

The good news:

Research shows strong evidence that Omega-3s lower triglyceride levels




Not all Omega-3s are the same:



MAT9001

A next generation prescription-only omega-3 fatty acid medication

MAT9001 – Unique engineered Omega-3 composition



 Severe Hypertriglyceridemia (≥500mg/dL)

Highest potency

Unique Mechanism of Action


Trace amounts of DHA

SPECIFICALLY DESIGNED TO TREAT DYSLIPIDEMIA

MATINAS

Quality by Design

Our targeted development activities and related clinical investigations may yield a stronger therapeutic profile compared to the currently-existing therapies.




MATINAS

Source: Matinas BioPharma research; unpublished 11

Exploratory studies show potent effects on human triglyceride levels

DPA VERSUS EPA IN POSTPRANDIAL TG CONTROL IN HUMANS Human Postprandial TG Levels (mmol/L) over 5 hours, after 7 days treatment (3-way cross-over, N=10)




MATINAS

Source: Linderborg et al.; PLEFA (2013) 88, 313-319 12

Early data suggests synergy with statin usage

STATIN INDUCED GENE-EXPRESSION COMPENSATORY EFFECTS AND N-3 DOCOSAPENTAENOIC ACID (DPA)

Relative levels of mRNA for HMG-CoA Reductase and PCSK9 in Rat Liver - In Vivo




Relative mRNA expression levels in Rat liver after 4 weeks dosing (400 mg DPA/kg*day)

MATINAS

Source: Matinas BioPharma research; unpublished 13

MAT9001 Development Plan



MATINAS

Management by Design

- President and CEO

George Bobotas, PhD – Chief Scientific Officer

Abdel Fawzy, PhD

 EVP Pharmaceutical & Supply Chain Development

Gary Gaglione, CPA – VP Finance, Acting CFO

Jerome Jabbour, JD

 Chief Business Officer & General Counsel





Acquired by GlaxoSmithKline for \$1.65B in 2007



\$16M raised to date

Board of Directors with Strong Pharma Experience

Herbert Conrad, Chairman

- Former President, Hoffmann LaRoche Pharmaceuticals
- Co-Founder/Director: Reliant Pharmaceuticals
- Chairman: Pharmasset, GenVec, Sapphire, Bone Care
- Director: Celldex, Reliant, Dura, Sicor, Savient

Stefano Ferrari, Director

- Murami Pharma, Bioseutica/KD-Pharma (leading manufacturer of omega-3 concentrates)
- Prospa, Societa Prodotti Antibiotici (developed first omega-3 based medication)

James Scibetta, Director

- Current CFO Pacira, Bioenvision/Genzyme, Merrimack
- Director: Labopharm, Nephros

Adam Stern, Director

- Aegis Capital Corp. / CEO, SternAegis Ventures
- Director: Organovo, InVivo Therapeutics, Prolor Biotech, LabStyle

Roelof Rongen, Director

- Reliant, Abbott/BASF Pharma, e-FAT, EPAX/Trygg Pharma, The Wilkerson Group, Arthur D. Little







Designed for Market Appetite							
Pre-Phase III	Pre-Phase III	Approved	Approved	Approved			
MATINAS MAT9001	Acasti ##Pharma "Capre"	Vascepa (icosapent ethyl)	AstraZeneca (A) Dentera Pharmaceuticals "Epanova"	LOVAZA omega-3-acid ethyl esters			
~\$30M	~\$105M	~\$300M	\$323M + \$125MM for milestone	\$1.65B			
Matinas BioPharma [MTNB] Market cap	Acasti [ACST] Market cap	Amarin [AMRN] Market cap	AstraZeneca acquired Omthera in 2013 after completion of Phase III	GSK acquired Reliant Pharmaceuticals in 2007			

MATINAS

Also in our Omega-3 pipeline

MAT8800

 Proprietary Omega-3 Discovery Program

Treating Fatty Liver Disease

NAFLD

 Common: 30% of U.S. population

A leading cause
of cirrhosis

NASH



MAT9001

Dyslipidemia & cardiovascular indications

Heart disease is the #1 killer

MATINAS



